The impact statement in SWOG's network operations grant application succinctly summarizes our work and our goals: By continuously improving inclusion, engagement, and scientific innovation, SWOG will enhance cancer clinical trial development and conduct, reducing the burden of human neoplasm. The SWOG National Clinical Trials Network Group has established itself as an innovative, collaborative, a n d cost-effective NCTN constituent. SWOG has 60 years of trial experience, and its work has led to the Food and Drug Administration approval of 14 regimens, changing and informing oncologic practice hundreds of time more. In our 2013 grant application, we promised to make unique contributions to the new NCTN enterprise, and we successfully did so over the last five years. We are strongly committed to furthering our efforts over the next six. SWOG designs and directs high-value, pathway- and immune- driven oncology research, with the goal of achieving practice-changing results that are meaningful to both persons affected by cancer and investigators. The group's current network includes more than 1,000 member sites, with 5,000 physicians who practice across the United States, Canada, South Korea, Mexico, Saudi Arabia, and South America. Twenty-three NCI-designated cancer centers number among our members, as do 22 Specialized Programs in Oncology Research Excellence. From early 2014 through mid-2017, SWOG investigators published more than 188 cancer treatment articles and abstracts, and enrolled 12,819 patients into NCTN therapeutic trials. SWOG actively collaborates in NCTN direct research and administrative functions and has developed training and education tools used throughout the network. SWOG's mission is to significantly improve lives through cancer clinical trials and translational research. The following guiding principles, ratified in 9/2017, are the foundation upon which we build to achieve that end: ? We make patients our absolute highest priority ? We ensure that the best science drives our research ? We embrace and encourage diversity in leadership and membership, to effectively solve problems in cancer ? We demand integrity, accountability, and ethical behavior in SWOG ? We foster and mentor young investigators, to ensure excellent clinical research for future generations Over the next grant cycle, we will provide an efficient, innovative, and nimble network capable of developing and conducting abroad framework of clinical and translational trials; we will meaningfully contribute to the NCTN; and we will help patients lead longer and meaningful lives. SWOG will remain an innovative force in the design of the next generation of oncologic therapies.
SWOG?s clinical and translational research will lead to a better understanding of the biology underlying neoplastic disease and will ultimately enable those potentially affected by cancer to lead longer, healthier lives.
|Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718|
|Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504|
|Phipps, Amanda I; Shi, Qian; Zemla, Tyler J et al. (2018) Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev 27:696-703|
|Ristau, Benjamin T; Manola, Judi; Haas, Naomi B et al. (2018) Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol 199:53-59|
|Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127|
|Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230|
|Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571|
|Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493|
|Herbst, Roy S; Redman, Mary W; Kim, Edward S et al. (2018) Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol 19:101-114|
|Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146|
Showing the most recent 10 out of 249 publications